The cell-line-derived subcutaneous tumor model in preclinical cancer research

被引:45
|
作者
Stribbling, Stephen M. [1 ]
Ryan, Anderson J. [1 ]
机构
[1] Univ Oxford, Dept Oncol, Oxford, England
关键词
GROWTH-FACTOR; HUMAN BREAST; IN-VIVO; ANTITUMOR-ACTIVITY; XENOGRAFT MODELS; PROSTATE-CANCER; T-CELLS; POTENT ANTITUMOR; MOUSE MODELS; NUDE-MICE;
D O I
10.1038/s41596-022-00709-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Tumor-bearing experimental animals are essential for preclinical cancer drug development. A broad range of tumor models is available, with the simplest and most widely used involving a tumor of mouse or human origin growing beneath the skin of a mouse: the subcutaneous tumor model. Here, we outline the different types of in vivo tumor model, including some of their advantages and disadvantages and how they fit into the drug-development process. We then describe in more detail the subcutaneous tumor model and key steps needed to establish it in the laboratory, namely: choosing the mouse strain and tumor cells; cell culture, preparation and injection of tumor cells; determining tumor volume; mouse welfare; and an appropriate experimental end point. The protocol leads to subcutaneous tumor growth usually within 1-3 weeks of cell injection and is suitable for those with experience in tissue culture and mouse experimentation. The authors describe a protocol for growing a tumor of mouse or human origin beneath the skin of a mouse, which is widely known as the subcutaneous mouse tumor model.
引用
收藏
页码:2108 / 2128
页数:21
相关论文
共 50 条
  • [41] Development of a MEL Cell-Derived Allograft Mouse Model for Cancer Research
    Kim, Young
    Choi, Sungwoo
    Lee, Seol Eui
    Kim, Ji Sook
    Son, Seung Han
    Lim, Young Soo
    Kim, Bang-Jin
    Ryu, Buom-Yong
    Uversky, Vladimir N.
    Lee, Young Jin
    Kim, Chul Geun
    CANCERS, 2019, 11 (11)
  • [42] Identifying cell lines across pan-cancer to be used in preclinical research as a proxy for patient tumor samples
    Bose, Banabithi
    Bozdag, Serdar
    COMMUNICATIONS BIOLOGY, 2024, 7 (01)
  • [43] The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding
    Alfano, Ivan
    Vora, Parvez
    Mummery, Rosemary S.
    Mulloy, Barbara
    Rider, Christopher C.
    BIOCHEMICAL JOURNAL, 2007, 404 (01) : 131 - 140
  • [44] Permanent rescue of lesioned neonatal motoneurons and enhanced axonal regeneration by adenovirus-mediated expression of glial cell-line-derived neurotrophic factor
    Baumgartner, BJ
    Shine, HD
    JOURNAL OF NEUROSCIENCE RESEARCH, 1998, 54 (06) : 766 - 777
  • [45] Medical gas plasma augments bladder cancer cell toxicity in preclinical models and patient-derived tumor tissues
    Gelbrich, Nadine
    Miebach, Lea
    Berner, Julia
    Freund, Eric
    Saadati, Fariba
    Schmidt, Anke
    Stope, Matthias
    Zimmermann, Uwe
    Burchardt, Martin
    Bekeschus, Sander
    JOURNAL OF ADVANCED RESEARCH, 2023, 47 : 209 - 223
  • [46] A human pituitary tumor-derived folliculostellate cell line
    Danila, DC
    Zhang, X
    Zhou, YL
    Dickersin, GR
    Fletcher, JA
    Hedley-Whyte, ET
    Selig, MK
    Johnson, SR
    Klibanski, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03): : 1180 - 1187
  • [47] Effect of Irradiation on Tumor Microenvironment and Bone Marrow Cell Migration in a Preclinical Tumor Model
    Kane, Jonathan L.
    Krueger, Sarah A.
    Hanna, Alaa
    Raffel, Thomas R.
    Wilson, George D.
    Madlambayan, Gerard J.
    Marples, Brian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (01): : 170 - 178
  • [48] Subcutaneous fat derived SVF efficiently improve the behavior of rat model after stroke: A preclinical study
    Hamidieh, A. A.
    Mohseni, R.
    Shoae-Hassani, A.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S331 - S331
  • [49] Pharmacokinetic of tumor FDG uptake in subcutaneous and orthotopic preclinical models of breast cancer - Influence of administration route
    Oudot, A.
    Vrigneaud, J. M.
    Raguin, O.
    Guillemin, M.
    Provent, P.
    Collin, B.
    Brunotte, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S477 - S477
  • [50] Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness
    Silvia Schmidtova
    Lambert C. J. Dorssers
    Katarina Kalavska
    Ad J. M. Gillis
    J. Wolter Oosterhuis
    Hans Stoop
    Svetlana Miklikova
    Zuzana Kozovska
    Monika Burikova
    Katarina Gercakova
    Erika Durinikova
    Michal Chovanec
    Michal Mego
    Lucia Kucerova
    Leendert H. J. Looijenga
    Cancer Cell International, 20